Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization -47% Improvement Relative Risk Hospitalization time -60% c19early.com/cbd Ramakrishnan et al. Cannabidiol for COVID-19 Prophylaxis Favors cannabidiol Favors control
Ramakrishnan, 6,291 patient cannabidiol prophylaxis study: 47% higher hospitalization [p=0.0001] https://c19p.org/ramakrishnan2
copied to clipboard
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes
Ramakrishnan et al., The Journal of Clinical Psychiatry, doi:10.4088/JCP.21m14332
29 Aug 2022    Source   PDF   Share   Tweet
Retrospective 6,291 COVID-19 patients in the USA, showing higher mean hospital admissions and higher maximum length of hospitalization with cannabis use disorder.
Results for cannabis use disorder patients may differ from other use of cannabis.
risk of hospitalization, 47.2% higher, RR 1.47, p < 0.001, treatment 20, control 6,271, mean number of admissions.
hospitalization time, 60.1% higher, relative time 1.60, p = 0.004, treatment 20, control 6,271, maximum length of hospitalization.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ramakrishnan et al., 29 Aug 2022, retrospective, USA, peer-reviewed, 4 authors, study period January 2020 - December 2020.
Contact: rajiv.radhakrishnan@yale.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit